Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN)

Annals of Oncology

Volumn 10, Issue 8, 1999, Pages 993-996

  Nole F ^a   Minchella, I ^a   Colleoni, M ^a   Orvieto, E ^a   Munzone, E ^a   De Braud, F ^a   Peruzzotti, G ^a   Martinelli, G ^a   Zampino, M G ^a   Catania, C ^a   Pizzamiglio, M ^a   Veronesi, P ^a   Zurrida, S ^a   Galimberti, V ^a   Goldhirsch, A ^a   Veronesi, U ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

5 fluorouracil; Breast cancer; Neoadjuvant; Primary chemotherapy; Vinorelbine

Indexed keywords

FLUOROURACIL; FOLINIC ACID; HORMONE RECEPTOR; KI 67 ANTIGEN; NAVELBINE; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ONCOGENE NEU; OUTPATIENT CARE; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0032834191     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008389106575     Document Type: Article

References (13)

1. Schabel FM Jr. Concepts for systemic treatment of micrometastases. Cancer 1975; 35: 15-24.
2. Fisher B, Bryant J, Wolmark N, Mamounas E et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-85.
3. Bonadonna G, Valagussa P, Zucali R et al. Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 1995; 45: 227-43.
4. Nolè F, de Braud F, Goldhirsch A et al. Phase I-II study of vinorelbine in combination with 5-FU and folinic acid as first line chemotherapy in metastatic breast cancer. A regimen with a low subjective toxic burden. Ann Oncol 1997; 8: 865-70.
5. Simon R. Confidence interval for reporting results of clinical trials. Ann Intern Med 1986; 105 (3): 429-35.
6. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961; 20: 346-53.
7. Veronesi U, Bonadonna G, Zurrida et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995; 5: 612-8.
8. Jacquillat C, Weil M, Baillet F et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990; 66: 119-29.
9. Weil M, Borel CH, Aurlerc G et al. Mature results in 477 breast cancer patients treated by neoadjuvant chemotherapy and exclusive radiotherapy. Fifth International Congress on Anti-Cancer Chemotherapy 1995; Abstr 763.
10. Smith IE, Walsh G, Jones A et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995; 13: 424-9.
11. Ellis P, Smith I, Ashley S et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 1998; 16:107-14.
12. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-93.
13. Colleoni M, Nolè F, Minchella I et al. Pre-operative chemotherapy and radiotherapy in Breast Cancer. Eur J Cancer 1998; 34: 641-5.